Table 2:

ETC Inhibitors

Inhibitor	glu	erastin	RSL3	IAA
No treatment	7.8 ± 0.4%	14.1 ± 4.4%	12.1 ± 2.5%	7.2 ± 1.3%
Rotenone (1 μM)	79.2 ± 11.6%^****	70.7 ± 1.0%^****	0%	15.3 ± 1.6 %
TTFA (100 μM)	79.1 ± 6.6%^****	65.5 ± 25.3%^***	0%	30.2 ± 4.0%^*
Antimycin A (1 μM)	67.9 ± 10.4%^****	73.2 ± 12.5%^****	0%	5.7 ± 9.8%
Myxothiazol (1 μM)	75.3 ± 4.9%^****	82.1 ± 2.3%^****	0%	0%
NaN₃ (5 mM)	89.9 ± 1.2%^****	85.2 ± 4.3%^****	0%	10.7 ± 9.5%
FCCP (0.5 μM)	63.3 ± 6.2%^****	72.6 ± 2.6%^****	0%	44.3 ± 17.7%^***

ETC inhibitors were tested for their ability to protect mouse HT22 hippocampal cells against glutamate, erastin and RSL3 toxicity at doses that induce 85%-95% cell death. Initially, a range of ETC inhibitor concentrations was tested based on literature reports. The most effective concentrations are reported here. The values presented are the average of a minimum of three independent experiments with all treatments done in triplicate.

p<0.05;

^***

p<0.001;

^****

p<0.0001 versus glutamate, erastin or RSL3 alone.